Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...

Nonalcoholic steatohepatitis (NASH ... With all the progress that has occurred, it is interesting that liver biopsy evaluation has retained an essential role in the clinical diagnosis of NASH ...

Liver biopsy and noninvasive markers should be used to stage and grade nonalcoholic steatohepatitis (NASH) in patients. Though liver biopsy remains the 'suboptimal' gold standard for diagnosis of ...

Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...

Fintel reports that on February 7, 2025, Citigroup initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Neutral ...

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Researchers describe successful tumor removal through the use of immunotherapy and targeted radiation therapy (TARE), in a patient previously considered ineligible for the procedure.

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

Discover a potential breakthrough in treating severe liver scarring with a safe and effective therapy, as revealed by a recent Cleveland Clinic-led study.

The associated ameliorated steatosis development suggests that inhibition of MCP-1 is an interesting novel approach for pharmacological treatment in liver inflammation and steatohepatitis. Funding ...

The American Cancer Society’s estimates for primary liver cancer and intrahepatic bile duct cancer in the United States for 2025 are: About 42,240 new cases (28,220 in men and 14,020 in women) will be ...